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Introduction: SALTIRE and RAAVE are the first two studies to evaluate the use of statins for aortic valve disease(AVD). We sought to determine if 
LDL lowering from statin therapy was associated with slowing of the progression of the change in the aortic valve area (AVA) associated with aortic 
stenosis.
Methods:  SALTIRE was a double-blind, placebo-controlled randomized trial, in which patients with AVD were randomly assigned to receive 
either atorvastatin 80mg or placebo. RAAVE was open-label, patients with asymptomatic moderate to severe AVD were treated with and without 
rosuvastatin 20 mg according to the NCEP guidelines for 18 months. We combined the data from SALTIRE and RAAVE for the LDL levels and the 
aortic valve area (AVA)s. We evaluated the % change in LDL to the % change in AVA in all patients using a one way ANOVA.
Results:  The mean age of the study population was 70.49 years. 60% of patients were male. In those patients who received statin therapy 
had a greater degree of LDL cholesterol lowering seen as the % change in LDL significantly associated with a lower change for aortic valve area 
demonstrating a slowing of progression with statin therapy (p<0.001 and R2=0.27). The percent change in the LDL for the treated patients was 47% 
and for the not treated was 2%. The percent change in the AVA for the treated was 5% and for the not treated was 15%.
Conclusion: In summary, these findings suggest that statin therapy may have a role in patients in the early stages of AVD. 
